Abstract
Objectives. —To report the initial experience of an international group of investigators in identifying mutations in the BRCA1 breast and ovarian cancer susceptibility gene, to assess the spectrum of such mutations in samples from patients with different family histories of cancer, and to determine the frequency of recurrent mutations.
Design. —Nine laboratories in North America and the United Kingdom tested for BRCA 1 mutations in DNA samples obtained from a total of 372 unrelated patients with breast or ovarian cancer largely chosen from high-risk families. Three of these laboratories also analyzed a total of 714 additional samples from breast or ovarian cancer cases, including 557 unselected for family history, for two specific mutations that had been found to recur in familial samples.
Participants. —A total of 1086 women with either breast or ovarian cancer.
Main Outcome Measure. —The detection of sequence variation in patients' DNA samples that is not found in sets of control samples.
Results. —BRCA 1 mutations have now been identified in a total of 80 patient samples. Thirty-eight distinct mutations were found among 63 mutations identified through a complete screen of the BRCA 1 gene. Three specific mutations appeared relatively common, occurring eight, seven, and five times, respectively. When specific tests for the two most common mutations were performed in larger sets of samples, they were found in 17 additional patients. Mutations predicted to result in a truncated protein accounted for 86% of the mutations detected by complete screening.
Conclusions. —The high frequency of protein-terminating mutations and the observation of many recurrent mutations found in a diverse set of samples could lead to a relatively simple diagnostic test for BRCA 1 mutations. More data must be accumulated to address specifically the sensitivity and specificity of such a diagnostic testing procedure and to better estimate the age-specific risk for breast and ovarian cancer associated with such mutations.(JAMA. 1995;273:535-541)
Design. —Nine laboratories in North America and the United Kingdom tested for BRCA 1 mutations in DNA samples obtained from a total of 372 unrelated patients with breast or ovarian cancer largely chosen from high-risk families. Three of these laboratories also analyzed a total of 714 additional samples from breast or ovarian cancer cases, including 557 unselected for family history, for two specific mutations that had been found to recur in familial samples.
Participants. —A total of 1086 women with either breast or ovarian cancer.
Main Outcome Measure. —The detection of sequence variation in patients' DNA samples that is not found in sets of control samples.
Results. —BRCA 1 mutations have now been identified in a total of 80 patient samples. Thirty-eight distinct mutations were found among 63 mutations identified through a complete screen of the BRCA 1 gene. Three specific mutations appeared relatively common, occurring eight, seven, and five times, respectively. When specific tests for the two most common mutations were performed in larger sets of samples, they were found in 17 additional patients. Mutations predicted to result in a truncated protein accounted for 86% of the mutations detected by complete screening.
Conclusions. —The high frequency of protein-terminating mutations and the observation of many recurrent mutations found in a diverse set of samples could lead to a relatively simple diagnostic test for BRCA 1 mutations. More data must be accumulated to address specifically the sensitivity and specificity of such a diagnostic testing procedure and to better estimate the age-specific risk for breast and ovarian cancer associated with such mutations.(JAMA. 1995;273:535-541)
| Original language | English |
|---|---|
| Pages (from-to) | 535-541 |
| Number of pages | 7 |
| Journal | JAMA: The Journal of the American Medical Association |
| Volume | 273 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 15 Feb 1995 |
Keywords
- breast cancer
- cancer screening
- cancer susceptibility
- ovary cancer
